Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

IDYA US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

IDYA US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

IDEAYA Biosciences, Inc.(IDYA US)

$31.83+0.341.08%Ext:$30.33-1.504.72%(Market Closed · 23:02:52 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

IDEAYA Biosciences, Inc.(IDYA US)

$31.83+0.341.08%Ext:$30.33-1.504.72%(Market Closed · 23:02:52 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

IDEAYA Biosciences, Inc. — Company Profile

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Yujiro S. Hata
Headquarters
South San Francisco, CA, US
IPO Date
May 23, 2019
Employees
145
Website
www.ideayabio.com

Key Metrics

Price
$37.36
Market Cap
$3.55B
Revenue (TTM)
$6.56M
Net Income (TTM)
$-98539000.00
EPS (TTM)
-1.11
P/E (TTM)
-25.36
P/B (TTM)
3.79
Dividend Yield
0.00%
ROE (TTM)
-10.51%
ROA (TTM)
-9.56%
Operating Margin
-16.55%
Beta
0.78

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Website
www.ideayabio.com
Location
South San Francisco, CA, US
Phone650 443 6209
Employees145
CEOYujiro S. Hata
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMay 23, 2019

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(500)

Expand
  • S-8Registration statement (employee benefit plan)3 Nov
  • 10-QQ3ended 30 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • Form 4Hata Yujiro S8 Oct
  • Form 144Hata Yujiro S6 Oct
  • SC 13GIDEAYA Biosciences, Inc.14 Aug
  • 10-QQ2ended 30 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • SC 13GIDEAYA Biosciences, Inc.31 Jul
  • Form 4Ruiz Briseno Andres9 Jul
  • Form 144Ruiz Briseno Andres7 Jul
  • 8-KSubmission of Matters to a Vote of Security Holders23 Jun
  • Form 4YARNO WENDY L18 Jun
  • Form 4Stein Jeffrey18 Jun
  • Form 4ROSEN TERRY J18 Jun
  • Form 4Morrison Scott W18 Jun
  • Form 4MACKEY CATHERINE J18 Jun
  • Form 4Hampton Malcolm Garret18 Jun
  • 8-KOther Events10 Jun
  • 424B5Prospectus filing (Rule 424(b)(5))9 Jun

News

  • IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors03:00PM
  • IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events4 Nov
  • IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates3 Nov
  • IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update3 Nov
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)30 Oct
  • IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?27 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?27 Oct
  • IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas23 Oct
  • IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma19 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock11 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened30 Sep
  • IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development28 Sep
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)25 Sep
  • Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA18 Sep
  • IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript10 Sep
  • IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma9 Sep
  • IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences1 Sep
  • IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer31 Aug
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)28 Aug
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)28 Aug

Mentions in Filings

  • … ceuticals, Inc.; and lasofoxifene, being developed by LeonaBio, Inc. There are also a number of KAT6 inhibitor product candidates in development that may compete with OP-3136 including prifetrastat and PF-08032562, being developed by Pfizer, MEN2312, being developed by Stemline Therapeutics, BG-75202 being developed by BeOne Medicines; IDE574, being developed by <strong>IDEAYA Biosciences, Inc.</strong>; and PRT13722, being developed by Prelude Therapeutics, Inc.
    Olema Pharmaceuticals, Inc.IDEAYA Biosciences, Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … 4), Qilu’s QLS31904 and Zelgen’s alveltamig (ZG006). Alternative approaches targeting DLL3 include ADCs, radioconjugates and bispecific antibodies, such as Zai Labs’ zocilurtatug (ZL-1310), Roche/Innovent’s IBI3009, <strong>IDEAYA Biosciences</strong>’ IDE849, Phanes Therapeutics’ Peluntamig (PT217) and Abdera’s ABD-147. The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our product candidates are ef …
    Zymeworks Inc.IDEAYA Biosciences, Inc.·ARS - Annual report to security holders·FY25·26 Oct
  • #\*Hims & Hers Health, Inc. 116,752 3,162,812 \*ICON PLC 2,034 366,629 \*ICU Medical, Inc. 71,075 10,654,143 \*Ideaya Biosciences, Inc. 245,421 7,900,102 \*Immunovant, Inc. 18 468 \*Indivior Pharmaceuticals, Inc. 51,936 1,837,496 \*InfuSystem Holdings, Inc. 59,155 488,620 \*Innovage Holding Corp. 10,196 56,588 \*Innoviva, Inc. 228,918 4,578,360 \*Inogen, Inc. 87,228 514,645
    Dimensional ETF TrustIDEAYA Biosciences, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … and Vice President, Immunology at BMS from 2000 to 2004. Dr. Daniels has served as a member of the board of directors of CSL Ltd. since December 2024. Dr. Daniels served as a member of the board of directors of <strong>Ideaya Biosciences, Inc.</strong> from June 2018 to January 2019, Novo Nordisk A/S from March 2016 to March 2021, and Cabaletta Bio, Inc. from October 2018 to June 2021. Dr. Daniels received his B.S. and M.S. degrees from Massachusetts Institu …
    Artiva Biotherapeutics, Inc.IDEAYA Biosciences, Inc.·ARS - Annual report to security holders·FY25·3 Aug
  • … 4 and Vice President, Immunology at BMS from 2000 to 2004. Dr. Daniels has served as a member of the board of directors of CSL Ltd. since December 2024. Dr. Daniels served as a member of the board of directors of <strong>Ideaya Biosciences, Inc.</strong> from June 2018 to January 2019, Novo Nordisk A/S from March 2016 to March 2021, and Cabaletta Bio, Inc. from October 2018 to June 2021. Dr. Daniels received his B.S. and M.S. degrees from Massachusetts Institute …
    Artiva Biotherapeutics, Inc.IDEAYA Biosciences, Inc.·DEF 14A - Definitive proxy statement·Q3 26·3 Aug
  • ##### Table of Contents **Joshua Bleharski, Ph.D.****, M.B.A.**, has served as a member of our board of directors since July 2026. Dr. Bleharski is currently the chief financial officer of <strong>IDEAYA Biosciences, Inc.</strong>, a precision medicine oncology company, which he joined in May 2025. Prior to that, Dr. Bleharski served in a variety of roles at J.P Morgan’s Healthcare Investment Banking group from July 2008 to April 2025, most recently as a Managin …
    Scribe Therapeutics, Inc.IDEAYA Biosciences, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q3 26·24 Jul

Key Stats

Trading

Px/Chg 1D$37.36 / -1.19%
Avg Volume1.22M
Beta0.78
Mkt Cap3.55B
FD Mkt Cap3.77B

Float

Shrs Out/Float95.08M / 87.08M
Short Float0.12%
Days to Cover6.08
Stock Repurchased$0.00

Current Valuation

EV3.42B
EV/EBITDA-23.32
EV/Sales15.20
P/B3.79
P/S15.77
FCF Yield-2.14%
ROE-10.51%
ROA-9.56%
Current Ratio10.74

Estimates

P/E-25.36
Est P/E0.00
Est EPS-1.07
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Aug '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-21.09-13.72-18.84-6.09-30.74-36.05
Price / Sales224.5115.8090.98238.85235.38541.51
Price / Book Value2.722.303.431.582.503.79
Price / Free Cash Flow-21.69-8.88-18.09-6.65-28.19-46.66
ENTERPRISE VALUE METRICS
Enterprise Value2,049.2739.71,973.51,606.72,502.73,423.4
Enterprise Value / Sales216.0814.5284.39229.53230.11521.86
Enterprise Value / EBITDA-20.55-13.08-18.11-5.94-30.49-35.15
Enterprise Value / EBIT-20.15-12.61-17.47-5.85-30.05-34.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue67.3%27.950.923.47.0218.7
Gross Income69.1%26.248.819.43.2214.1
EBITDA22.8%-48.0-56.6-109.0-270.6-109.1
EBIT22.9%-49.8-58.7-113.0-274.5-113.7
Net Income22.9%-49.8-58.7-113.0-274.5-113.7
EPS (Diluted)-2.4%-1.41-1.42-1.96-3.36-1.28
BALANCE SHEET
Cash & ST Inv26.9%246.8364.8525.1676.3639.4
Total Assets30.6%381.3388.0649.31,124.11,109.3
Total Liabilities2%79.838.528.264.986.4
Total Shareholder Equity35.7%301.5349.5621.11,059.11,022.9
CASH FLOW
Net Operating Cash Flow6.3%-55.8-87.2-115.2-247.6-71.1
Cap Ex-2.7%-2.6-3.4-2.4-3.9-2.4
Free Cash Flow5.9%-58.4-90.6-117.6-251.4-73.5

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)30.57
Basic Shares95.08
Market Cap2,906.7
Diluted Shares102.94
Fully Diluted Shares Outstanding102.94
Fully Diluted Market Cap3,147.0
+Consolidated Debt29.7
−In-the-Money Convertible Debt—
+Capital Leases29.7
+Operating Leases—
−Cash & Equivalents-261.5
−Short-term Investments-577.1
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value2,674.9

Segment data

Revenue

by Products and services

  • Research And Development Services100%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

IDEAYA Biosciences, Inc. — Company Profile

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UQ
CEO
Yujiro S. Hata
Headquarters
South San Francisco, CA, US
IPO Date
May 23, 2019
Employees
145
Website
www.ideayabio.com

Key Metrics

Price
$37.36
Market Cap
$3.55B
Revenue (TTM)
$6.56M
Net Income (TTM)
$-98539000.00
EPS (TTM)
-1.11
P/E (TTM)
-25.36
P/B (TTM)
3.79
Dividend Yield
0.00%
ROE (TTM)
-10.51%
ROA (TTM)
-9.56%
Operating Margin
-16.55%
Beta
0.78

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

Website
www.ideayabio.com
Location
South San Francisco, CA, US
Phone650 443 6209
Employees145
CEOYujiro S. Hata
Sector
Health Care
Industry
Pharmaceuticals
IPO DateMay 23, 2019

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(500)

Expand
  • S-8Registration statement (employee benefit plan)3 Nov
  • 10-QQ3ended 30 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • Form 4Hata Yujiro S8 Oct
  • Form 144Hata Yujiro S6 Oct
  • SC 13GIDEAYA Biosciences, Inc.14 Aug
  • 10-QQ2ended 30 Jun 20264 Aug
  • 8-KResults of Operations and Financial Condition4 Aug
  • SC 13GIDEAYA Biosciences, Inc.31 Jul
  • Form 4Ruiz Briseno Andres9 Jul
  • Form 144Ruiz Briseno Andres7 Jul
  • 8-KSubmission of Matters to a Vote of Security Holders23 Jun
  • Form 4YARNO WENDY L18 Jun
  • Form 4Stein Jeffrey18 Jun
  • Form 4ROSEN TERRY J18 Jun
  • Form 4Morrison Scott W18 Jun
  • Form 4MACKEY CATHERINE J18 Jun
  • Form 4Hampton Malcolm Garret18 Jun
  • 8-KOther Events10 Jun
  • 424B5Prospectus filing (Rule 424(b)(5))9 Jun

News

  • IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors03:00PM
  • IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events4 Nov
  • IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates3 Nov
  • IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update3 Nov
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)30 Oct
  • IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?27 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) Shares Cross Below 200 Day Moving Average – Should You Sell?27 Oct
  • IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas23 Oct
  • IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma19 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) CEO Sells $985,304.58 in Stock11 Oct
  • IDEAYA Biosciences (NASDAQ:IDYA) Stock Jumps 4.8% – Here’s What Happened30 Sep
  • IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development28 Sep
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)25 Sep
  • Squarepoint Ops LLC Has $940,000 Holdings in IDEAYA Biosciences, Inc. $IDYA18 Sep
  • IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript10 Sep
  • IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma9 Sep
  • IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences1 Sep
  • IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer31 Aug
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)28 Aug
  • IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)28 Aug

Mentions in Filings

  • … ceuticals, Inc.; and lasofoxifene, being developed by LeonaBio, Inc. There are also a number of KAT6 inhibitor product candidates in development that may compete with OP-3136 including prifetrastat and PF-08032562, being developed by Pfizer, MEN2312, being developed by Stemline Therapeutics, BG-75202 being developed by BeOne Medicines; IDE574, being developed by <strong>IDEAYA Biosciences, Inc.</strong>; and PRT13722, being developed by Prelude Therapeutics, Inc.
    Olema Pharmaceuticals, Inc.IDEAYA Biosciences, Inc.·10-Q - Quarterly report Q3·Q3 26·10 Nov
  • … 4), Qilu’s QLS31904 and Zelgen’s alveltamig (ZG006). Alternative approaches targeting DLL3 include ADCs, radioconjugates and bispecific antibodies, such as Zai Labs’ zocilurtatug (ZL-1310), Roche/Innovent’s IBI3009, <strong>IDEAYA Biosciences</strong>’ IDE849, Phanes Therapeutics’ Peluntamig (PT217) and Abdera’s ABD-147. The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our product candidates are ef …
    Zymeworks Inc.IDEAYA Biosciences, Inc.·ARS - Annual report to security holders·FY25·26 Oct
  • #\*Hims & Hers Health, Inc. 116,752 3,162,812 \*ICON PLC 2,034 366,629 \*ICU Medical, Inc. 71,075 10,654,143 \*Ideaya Biosciences, Inc. 245,421 7,900,102 \*Immunovant, Inc. 18 468 \*Indivior Pharmaceuticals, Inc. 51,936 1,837,496 \*InfuSystem Holdings, Inc. 59,155 488,620 \*Innovage Holding Corp. 10,196 56,588 \*Innoviva, Inc. 228,918 4,578,360 \*Inogen, Inc. 87,228 514,645
    Dimensional ETF TrustIDEAYA Biosciences, Inc.·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … and Vice President, Immunology at BMS from 2000 to 2004. Dr. Daniels has served as a member of the board of directors of CSL Ltd. since December 2024. Dr. Daniels served as a member of the board of directors of <strong>Ideaya Biosciences, Inc.</strong> from June 2018 to January 2019, Novo Nordisk A/S from March 2016 to March 2021, and Cabaletta Bio, Inc. from October 2018 to June 2021. Dr. Daniels received his B.S. and M.S. degrees from Massachusetts Institu …
    Artiva Biotherapeutics, Inc.IDEAYA Biosciences, Inc.·ARS - Annual report to security holders·FY25·3 Aug
  • … 4 and Vice President, Immunology at BMS from 2000 to 2004. Dr. Daniels has served as a member of the board of directors of CSL Ltd. since December 2024. Dr. Daniels served as a member of the board of directors of <strong>Ideaya Biosciences, Inc.</strong> from June 2018 to January 2019, Novo Nordisk A/S from March 2016 to March 2021, and Cabaletta Bio, Inc. from October 2018 to June 2021. Dr. Daniels received his B.S. and M.S. degrees from Massachusetts Institute …
    Artiva Biotherapeutics, Inc.IDEAYA Biosciences, Inc.·DEF 14A - Definitive proxy statement·Q3 26·3 Aug
  • ##### Table of Contents **Joshua Bleharski, Ph.D.****, M.B.A.**, has served as a member of our board of directors since July 2026. Dr. Bleharski is currently the chief financial officer of <strong>IDEAYA Biosciences, Inc.</strong>, a precision medicine oncology company, which he joined in May 2025. Prior to that, Dr. Bleharski served in a variety of roles at J.P Morgan’s Healthcare Investment Banking group from July 2008 to April 2025, most recently as a Managin …
    Scribe Therapeutics, Inc.IDEAYA Biosciences, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q3 26·24 Jul

Key Stats

Trading

Px/Chg 1D$37.36 / -1.19%
Avg Volume1.22M
Beta0.78
Mkt Cap3.55B
FD Mkt Cap3.77B

Float

Shrs Out/Float95.08M / 87.08M
Short Float0.12%
Days to Cover6.08
Stock Repurchased$0.00

Current Valuation

EV3.42B
EV/EBITDA-23.32
EV/Sales15.20
P/B3.79
P/S15.77
FCF Yield-2.14%
ROE-10.51%
ROA-9.56%
Current Ratio10.74

Estimates

P/E-25.36
Est P/E0.00
Est EPS-1.07
Est PEG0.00

Valuation

Metric5Yr AvgMay '23Aug '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-21.09-13.72-18.84-6.09-30.74-36.05
Price / Sales224.5115.8090.98238.85235.38541.51
Price / Book Value2.722.303.431.582.503.79
Price / Free Cash Flow-21.69-8.88-18.09-6.65-28.19-46.66
ENTERPRISE VALUE METRICS
Enterprise Value2,049.2739.71,973.51,606.72,502.73,423.4
Enterprise Value / Sales216.0814.5284.39229.53230.11521.86
Enterprise Value / EBITDA-20.55-13.08-18.11-5.94-30.49-35.15
Enterprise Value / EBIT-20.15-12.61-17.47-5.85-30.05-34.74

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue67.3%27.950.923.47.0218.7
Gross Income69.1%26.248.819.43.2214.1
EBITDA22.8%-48.0-56.6-109.0-270.6-109.1
EBIT22.9%-49.8-58.7-113.0-274.5-113.7
Net Income22.9%-49.8-58.7-113.0-274.5-113.7
EPS (Diluted)-2.4%-1.41-1.42-1.96-3.36-1.28
BALANCE SHEET
Cash & ST Inv26.9%246.8364.8525.1676.3639.4
Total Assets30.6%381.3388.0649.31,124.11,109.3
Total Liabilities2%79.838.528.264.986.4
Total Shareholder Equity35.7%301.5349.5621.11,059.11,022.9
CASH FLOW
Net Operating Cash Flow6.3%-55.8-87.2-115.2-247.6-71.1
Cap Ex-2.7%-2.6-3.4-2.4-3.9-2.4
Free Cash Flow5.9%-58.4-90.6-117.6-251.4-73.5

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)30.57
Basic Shares95.08
Market Cap2,906.7
Diluted Shares102.94
Fully Diluted Shares Outstanding102.94
Fully Diluted Market Cap3,147.0
+Consolidated Debt29.7
−In-the-Money Convertible Debt—
+Capital Leases29.7
+Operating Leases—
−Cash & Equivalents-261.5
−Short-term Investments-577.1
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value2,674.9

Segment data

Revenue

by Products and services

  • Research And Development Services100%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Novartis Ag

NVS US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US